Healthcare
T2 Biosystems, Inc.(TTOO)
Live Price
Offline$0.0005
+25.00% today
1Y Change
-99.62%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- โ
- Revenue Growth
- -67.8%
- EPS Growth
- +98.4%
- Dividend Yield
- 0.0%
Coverage: 220 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
T2 Biosystems, Inc. (TTOO) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.6% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -67.8%, EPS growth of +98.4%, a dividend yield of 0.0%. What stands out right now is revenue -67.8%, EPS +98.4%, free cash flow +5.2% with operating margin -690.4% and ROIC -230.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TTOO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-67.8% vs +7.6% peer median
Operating Margin
Below sector median
-690.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -67.8% and EPS is at +98.4%, with operating margin around -690.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -36.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +0.0% | +14.3% | +185.7% |
2026 Mar 4, 2026 | โ | +0.0% | -86.7% | -93.3% |
2025 Oct 6, 2025 | โ | +9.1% | -36.4% | +9.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TTOO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TTOO Max Drawdown
-99.93%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TTOO and SPY.
Company Overview
T2 Biosystems, Inc.
Other OTC
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
- Leadership
- Craig R. Jalbert
- IPO Date
- Aug 7, 2014
- Employees
- 113
- Street Address
- 101 Hartwell Avenue
- Mailing
- Lexington, MA, 02421
- Region
- Lexington, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 761 4646
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- -67.8%
- EPS
- +98.4%
- Free Cash Flow
- +5.2%
Profitability
- Gross Margin
- -113.6%
- Operating Margin
- -690.4%
- Net Margin
- -696.2%
- ROE
- 147.3%
- ROIC
- -230.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.45
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.